These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
761 related items for PubMed ID: 24690280
1. [Extension study and evaluation of the therapeutic response in a patient with metastatic lung adenocarcinoma using sequential study with ¹⁸F-FDG PET-CT and ¹⁸F-fluoride PET-CT]. Moragas M, Soler M, Riera E, García JR. Rev Esp Med Nucl Imagen Mol; 2015; 34(1):45-8. PubMed ID: 24690280 [Abstract] [Full Text] [Related]
2. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography. Ak I, Sivrikoz MC, Entok E, Vardareli E. Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657 [Abstract] [Full Text] [Related]
3. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Damle NA, Bal C, Bandopadhyaya GP, Kumar L, Kumar P, Malhotra A, Lata S. Jpn J Radiol; 2013 Apr; 31(4):262-9. PubMed ID: 23377765 [Abstract] [Full Text] [Related]
4. Comparison of 18F-FDG PET/CT scan and 99mTc-MDP bone scintigraphy in detecting bone metastasis in head and neck tumors. Al-Bulushi NK, Abouzied ME. Nucl Med Commun; 2016 Jun; 37(6):583-8. PubMed ID: 26813992 [Abstract] [Full Text] [Related]
5. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by 18F-FDG PET/CT. The role of 99mTc-MDP. Pietrzak A, Czepczynski R, Wierzchoslawska E, Cholewinski W. Hell J Nucl Med; 2017 Jun; 20(3):237-240. PubMed ID: 29177262 [Abstract] [Full Text] [Related]
8. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A. J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167 [Abstract] [Full Text] [Related]
9. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Qiu ZL, Xue YL, Song HJ, Luo QY. Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353 [Abstract] [Full Text] [Related]
13. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Iagaru A, Mittra E, Dick DW, Gambhir SS. Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710 [Abstract] [Full Text] [Related]
14. (18)F-FDG PET/CT versus bone scintigraphy in the follow-up of gastric cancer. Sollini M, Calabrese L, Zangheri B, Erba PA, Gramaglia A, Gasparini M. Rev Esp Med Nucl Imagen Mol; 2016 Apr; 35(2):121-3. PubMed ID: 26653282 [Abstract] [Full Text] [Related]
15. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases. Ozcan Kara P, Kara T, Kara Gedik G, Sari O, Sahin O. Rev Esp Med Nucl; 2011 Apr; 30(2):94-6. PubMed ID: 21342722 [Abstract] [Full Text] [Related]
16. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer. Lee JW, Lee SM, Lee HS, Kim YH, Bae WK. Ann Nucl Med; 2012 Oct; 26(8):627-33. PubMed ID: 22729551 [Abstract] [Full Text] [Related]
20. The value of quantitative analysis in 18F-NaF PET/CT. Lapa P, Marques M, Costa G, Lima JP. Rev Esp Med Nucl Imagen Mol; 2017 Oct; 36(2):78-84. PubMed ID: 27793635 [Abstract] [Full Text] [Related] Page: [Next] [New Search]